Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
4D Molecular Therapeutics | FDMT | Nov 20, 2024 | 8.41 | -3.00 |
51Talk Online Education Group ADR | COE | Nov 20, 2024 | 15.49 | -0.26 |
5E Advanced Materials | FEAM | Nov 20, 2024 | 0.44 | +0.32 |
60 Degrees Pharmaceuticals | SXTP | Nov 20, 2024 | 0.92 | 0.00 |
7-10 Yr Trsy Bear 3X Direxion | TYO | Nov 20, 2024 | 14.44 | +0.41 |
7-10 Yr Trsy Bull 3X Direxion | TYD | Nov 20, 2024 | 24.48 | -0.45 |
7-10 Yr Trsy Ishares | IEF | Nov 20, 2024 | 93.59 | -0.15 |
89bio | ETNB | Nov 20, 2024 | 7.98 | -0.13 |
8x8 | EGHT | Nov 20, 2024 | 2.84 | +5.58 |
908 Devices | MASS | Nov 20, 2024 | 2.56 | +3.23 |
99 Acquisition Group | NNAGU | Nov 20, 2024 | 10.60 | 0.00 |
9F ADR | JFU | Nov 20, 2024 | 1.28 | +7.56 |
A SPAC II Acquisition | ASCB | Nov 20, 2024 | 11.19 | 0.00 |
A-Mark Precious Metals | AMRK | Nov 20, 2024 | 30.83 | +2.46 |
a.k.a Brands | AKA | Nov 20, 2024 | 18.75 | -1.32 |
A.O Smith | AOS | Nov 20, 2024 | 71.75 | +0.48 |
A10 Networks | ATEN | Nov 20, 2024 | 16.48 | +0.49 |
A2Z Cust2Mate Solutions | AZ | Nov 20, 2024 | 6.44 | -3.16 |
AA Mission Acquisition | AAM | Nov 20, 2024 | 10.05 | 0.00 |
AAA - A Rated Corporate Bond Ishares | QLTA | Nov 20, 2024 | 47.37 | -0.25 |
Aadi Bioscience | AADI | Nov 20, 2024 | 2.22 | +0.45 |
AAON | AAON | Nov 20, 2024 | 132.05 | +0.68 |
AAR | AIR | Nov 20, 2024 | 67.54 | +0.28 |
Abacus Life | ABL | Nov 20, 2024 | 8.86 | +5.10 |
Abbott Laboratories | ABT | Nov 20, 2024 | 115.93 | -1.02 |
AbbVie | ABBV | Nov 20, 2024 | 167.76 | +0.71 |
AbCellera Biologics | ABCL | Nov 20, 2024 | 2.67 | -1.48 |
Abeona Therapeutics | ABEO | Nov 20, 2024 | 5.75 | -2.38 |
Abercrombie & Fitch | ANF | Nov 20, 2024 | 136.81 | -4.05 |
Aberdeen Asia-Pacificome Fund | FAX | Nov 20, 2024 | 15.92 | +0.06 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.